Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and connected persons, specifically regarding awards under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions.
| Metric | Value |
|---|---|
| Ordinary Share Price (Feb 27, 2013) | £14.54 |
| ADS Price (Feb 27, 2013) | US$44.27 |
Material Changes
The filing details changes in share interests resulting from an award made on February 28, 2013:
- Mr P Thomson: Connected person Mrs K Thomson received 3,040 Ordinary Shares.
- Dr M Slaoui (Executive Director): Connected person Mrs K Slaoui received 2,030 ADS.
Vesting of these awards is subject to meeting performance criteria over a three-year period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard vesting conditions of the Performance Share Plan.
Key Facts for Investor Verification
- Verify the vesting schedule and specific performance criteria attached to the February 28, 2013 Performance Share Plan awards.
- Confirm the total number of shares and ADS held by the connected persons of Mr P Thomson and Dr M Slaoui post-transaction.
- Review the company's broader annual report (Form 20-F) for comprehensive financial performance data, as this filing contains no operational metrics.